M1 Polarized Microglia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
M1 microglia represent the classically activated, pro-inflammatory phenotype that responds to pathogens and damage signals. They are the effector cells of the innate immune system in the central nervous system (CNS), producing high levels of pro-inflammatory cytokines, chemokines, and reactive nitrogen and oxygen species. M1 polarization is induced by stimuli such as lipopolysaccharide (LPS), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) [1].
The M1/M2 paradigm, though somewhat simplified, provides a useful framework for understanding microglia phenotypic diversity. M1 microglia are characterized by elevated expression of major histocompatibility complex class II (MHC-II) molecules, cluster of differentiation 86 (CD86), and inducible nitric oxide synthase (iNOS), enabling antigen presentation and production of neurotoxic molecules.
M1-polarized microglia express a distinct repertoire of surface markers and secreted molecules:
| Marker | Type | Function |
|---|---|---|
| CD16/32 (FcγRIII/II) | Fc gamma receptors | Mediate antibody-dependent cellular cytotoxicity |
| CD86 | Co-stimulatory molecule | Provides secondary signal for T-cell activation |
| iNOS | Enzyme | Produces nitric oxide (NO) from L-arginine |
| MHC-II (HLA-DR) | Surface protein | Presents antigens to CD4+ T-cells |
| CD68 | Scavenger receptor | Marker of microglial activation |
| TNF-α | Cytokine | Pro-inflammatory signaling |
| IL-1β | Cytokine | Fever, inflammation, acute phase response |
| IL-6 | Cytokine | Pro-inflammatory and acute phase response |
| CXCL10 | Chemokine | Recruits immune cells |
M1 polarization is driven by several key signaling pathways:
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway is central to M1 polarization. Toll-like receptor (TLR) engagement activates NF-κB, leading to transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and iNOS [2].
IFN-γ binding to its receptor activates JAK1/STAT1 signaling, promoting transcription of M1-associated genes. STAT1 directly upregulates iNOS and MHC-II expression.
p38 MAPK and JNK pathways contribute to M1 polarization by regulating cytokine production and cellular stress responses.
M1 microglia perform several critical functions:
M1 microglia secrete pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12, IL-18) that coordinate the inflammatory response to pathogens and injury.
Through phagocytosis and production of antimicrobial molecules, M1 microglia eliminate pathogens and cellular debris.
Express MHC-II molecules allow M1 microglia to present antigens to CD4+ T-cells, bridging innate and adaptive immunity.
Production of nitric oxide (via iNOS), reactive oxygen species (ROS), and reactive nitrogen species (RNS) can be cytotoxic to pathogens but also damage nearby neurons and oligodendrocytes.
NADPH oxidase (NOX2) and iNOS produce superoxide anion and nitric oxide, respectively, which can combine to form peroxynitrite—a highly damaging reactive nitrogen species.
M1 microglia are prominently involved in Alzheimer's disease pathogenesis. Amyloid-beta (Aβ) plaques and tau pathology activate microglia via TLRs and the NLRP3 inflammasome, driving M1 polarization [3]. The resulting chronic neuroinflammation contributes to:
In Parkinson's disease, M1 microglia are activated by α-synuclein aggregates, neuromelanin, and damage-associated molecular patterns (DAMPs). This contributes to:
M1 microglia in ALS produce neurotoxic cytokines and oxidative stress that accelerate motor neuron degeneration. Studies show M1 microglial markers correlate with disease progression [4].
M1 microglia contribute to demyelination and lesion formation in MS. They attack myelin sheaths and produce factors that inhibit oligodendrocyte precursor cell (OPC) differentiation and remyelination.
| Therapeutic | Mechanism | Status |
|---|---|---|
| Minocycline | Inhibits microglial activation | Clinical trials for ALS, AD |
| Dexanabinol | NF-κB inhibition | Phase I/II for neuroprotection |
| NR1 (_MEMantine) | NMDA receptor modulation | Approved for AD |
| TNF-α inhibitors | Block pro-inflammatory cytokine | Investigational |
Promoting the M2 (neuroprotective) phenotype is a promising strategy:
Targeting NADPH oxidase to reduce oxidative stress:
The study of M1 Polarized Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tang Y, Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. J Neuroinflammation. 2016;13(1):94. PMID:26768242.
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-934. PMID:22002745.
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. PMID:25792098.
Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237(1):122-130. PMID:22735495.
Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98. PMID:24889886.
Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69. PMID:17180163.